Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.53 |
| ▸ | CCR2 | P41597 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528598 | 1.00 | ROCK2 (0.54) | ROCK2ROCK1CCR2 | |
| SCHEMBL4477690 | 0.94 | ROCK2 (0.56) | ROCK2ROCK1CCR2 | |
| SCHEMBL5662572 | 0.94 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL29862650 | 0.94 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL1509605 | 0.91 | ROCK2 (0.49) | ROCK2ROCK1CCR2 | |
| SCHEMBL1509653 | 0.89 | ROCK2 (0.48) | ROCK2ROCK1CCR2 | |
| SCHEMBL1509607 | 0.89 | ROCK2 (0.48) | ROCK2ROCK1CCR2 | |
| SCHEMBL28834243 | 0.88 | USP30 (0.52) | — | |
| SCHEMBL28834245 | 0.88 | USP30 (0.52) | — | |
| SCHEMBL28834280 | 0.88 | USP30 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-8158796-B2 | Process for the preparation of Rho-kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158796-B2 | Process for the preparation of Rho-kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009154940-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885CCR2 1243/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 3233/4885 |
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CCR2 3120/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 3233/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.